Antibodies specific for CD70 and their uses
AssigneePfizer Inc.
InventorsSiler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
Claims36
An isolated antibody, which specifically binds to Cluster of Differentiation 70 (CD70), wherein the antibody comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein:
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:
- 97,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:
- 100,
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:
- 102;
- or
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:
- 98,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:
- 101,
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:
- 102;
- or
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:
- 99,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:
- 100,
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:
- 102;
- and
- wherein
- the VL CDR1 comprises the amino acid sequence of SEQ ID NO:
- 217,
- the VL CDR2 comprises the amino acid sequence of SEQ ID NO:
- 218, and
- the VL CDR3 comprises the amino acid sequence of SEQ ID NO:
- 219.
A bispecific antibody wherein the bispecific antibody is a full-length antibody, comprising a first antigen binding site of the bispecific antibody specifically binding to a target antigen, and comprising a second antigen binding site of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antigen binding site comprises a heavy chain variable (VH) region comprising a VH CDR1, VH CDR2, and VH CDR3 and a light chain variable (VL) region comprising a VL CDR1, VL CDR2, and VL CDR3, wherein the VH region comprises the amino acid sequence of SEQ ID NO:
- 18 and the VL region comprises the amino acid sequence of SEQ ID NO:
- 17.
A bispecific antibody wherein the bispecific antibody is a full-length antibody, comprising a first antigen binding site of the bispecific antibody specifically binding to CD70, and comprising a second antigen binding site of the bispecific antibody capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen located on the human immune effector cell, wherein the first antigen binding site comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3 wherein:
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:
- 97,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:
- 100,
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:
- 102;
- or
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:
- 98,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:
- 101,
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:
- 102;
- or
- the VH CDR1 comprises the amino acid sequence of SEQ ID NO:
- 99,
- the VH CDR2 comprises the amino acid sequence of SEQ ID NO:
- 100,
- the VH CDR3 comprises the amino acid sequence of SEQ ID NO:
- 102;
- and
- wherein
- the VL CDR1 comprises the amino acid sequence of SEQ ID NO:
- 217,
- the VL CDR2 comprises the amino acid sequence of SEQ ID NO:
- 218, and
- the VL CDR3 comprises the amino acid sequence of SEQ ID NO:
- 219.
An isolated antibody, which specifically binds to Cluster of Differentiation 70 (CD70), wherein the antibody comprises a heavy chain variable (VH) region comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3, and a light chain variable (VL) region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL region comprises the amino acid sequence of SEQ ID NO:
- 17 and the VH region comprises the amino acid sequence of SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.